Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Provention Bio plans to begin a Phase 2a trial of PRV-3279 in systemic lupus erythematosus (SLE) in the second half of 2021 and expects a portion of such trial to be conducted in China.
Lead Product(s): PRV-3279
Therapeutic Area: Immunology Product Name: PRV-3279
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Provention Bio
Deal Size: $293.0 million Upfront Cash: $6.0 million
Deal Type: Collaboration February 17, 2021